摘要
乳腺癌是女性最常见的肿瘤,大约75%的乳腺癌表达雌激素受体和/或孕激素受体。激素受体阳性的转移性乳腺癌患者通常采用内分泌治疗,然而由于内分泌治疗耐药的产生,其应用受到了限制。近年来发现,PI3K/Akt(丝氨酸/苏氨酸激酶)信号通路在乳腺癌的发展中发挥着重要作用。本文对PI3K/Akt信号通路在乳腺癌内分泌治疗耐药中的作用进行了综述,以期为雌激素受体阳性乳腺癌治疗提供新对策。
Breast cancer is the most common cancer among women, about 75% of breast cancers express the estrogen receptor and/or the progesterone receptor. Patients with hormone receptor-positive metastatic breast cancer are usually treated with endocrine therapy. However, due to the generation of endocrine therapy resistance, its application has been limited. Recently discovered, PI3K/Akt signaling pathway plays an important role in the development of breast cancer. In this paper, we specifically analyze the role of the PI3K/Akt signaling pathway in breast cancer endocrine therapy resistance, in order to offer new strategies to estrogen receptor-positive breast cancer.
出处
《标记免疫分析与临床》
CAS
2015年第12期1287-1292,共6页
Labeled Immunoassays and Clinical Medicine
基金
苏州市科技发展计划项目
项目编号:SYS201458
